Incyte announced that multiple abstracts highlighting data from its dermatology portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) Congress, on Sept. 7-10, 2022 in Milan and virtually.
The presentations will feature Phase 3 studies highlighting clinical trial date for ruxolitnib cream in vitiligo, as well as data on their oral JAK1 inhibitor, povorcitinib (formerly INCB054707) in hidradenitis suppurativa (HS).
Related: FDA Approves Opzelura Cream for Treatment of Vitiligo
“We are excited for the opportunity to present research from our growing dermatology portfolio at this year’s EADV Congress, including data on ruxolitinib cream in vitiligo, on the heels of our recent U.S. Food and Drug Administration (FDA) approval in this indication,” said Jim Lee, M.D., Ph.D., group vice president, inflammation & autoimmunity, for Incyte. “We additionally look forward to several presentations of data on our oral JAK1 inhibitor, povorcitinib (formerly INCB054707), which we are advancing into Phase 3 development for hidradenitis suppurativa.”
